Latest Ratios: P/E Ratio -0.4x · EV/EBITDA N/A · ROE -226.2%. (2012–2024 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $11M | $6M | $12M | $12M | $56M | $14M | $14M | $9M | $15M | $34M | $23M |
| Enterprise Value | $11M | $6M | $3M | $9M | $31M | $7M | $6M | $152700 | $8M | $22M | $13M |
| P/E Ratio → | -0.43 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | 139.64 | 130.20 |
| P/B Ratio | — | — | 0.51 | 0.30 | 1.10 | 0.85 | 2.20 | 0.67 | 2.57 | 3.27 | 1.78 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | 91.94 | 75.91 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | 46.7% | 46.8% |
| Operating Margin | — | — | — | — | — | — | — | — | — | -3713.9% | -7204.0% |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | -3617.2% | -7104.0% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -226.2% | -226.2% | -54.1% | -41.5% | -51.3% | -122.5% | -143.6% | -111.8% | -119.8% | -76.6% | -165.2% |
| ROA | -198.1% | -198.1% | -49.9% | -37.8% | -45.7% | -95.3% | -111.3% | -90.7% | -96.7% | -64.0% | -106.5% |
| ROIC | -287.7% | -287.7% | -54.6% | -47.3% | -75.4% | -259.7% | -613.5% | -493.0% | — | -671.6% | -424.1% |
| ROCE | -233.2% | -233.2% | -58.7% | -42.8% | -50.7% | -119.7% | -141.8% | -113.1% | -115.8% | -75.0% | -137.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | 0.02 | 0.02 | 0.02 | 0.07 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | -0.37 | -0.08 | -0.50 | -0.45 | -1.16 | -0.66 | -1.18 | -1.12 | -0.74 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -2883.22 | -2883.22 | -1483.62 | -1669.50 | -1332.38 | -1161.00 | -1758.63 | -1580.43 | -1428.71 | -1294.57 | -265.17 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.15 | 0.15 | 18.69 | 12.51 | 13.05 | 6.18 | 3.01 | 6.75 | 4.74 | 8.69 | 7.20 |
| Quick Ratio | 0.15 | 0.15 | 18.69 | 12.43 | 13.02 | 6.11 | 2.94 | 6.75 | 4.80 | 8.66 | 9.57 |
| Cash Ratio | 0.15 | 0.15 | 18.61 | 12.24 | 12.76 | 5.97 | 2.74 | 6.40 | 4.48 | 8.51 | 6.85 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | 0.02 | 0.01 |
| Inventory Turnover | 1.53 | — | — | 1.53 | 1.42 | 0.71 | 0.60 | — | — | 2.71 | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $6M | $6M | $6M | $4M | $2M | $399302 | $202900 | $72749 | $60412 | $49658 |
Imminent Liquidity Exhaustion
As reported in financial statements, Check-Cap's ROIC has consistently trended in negative territory, reaching -36.0% in 2024Q1, which underscores the firm's inability to generate any productive return on invested capital while it remains trapped in a prolonged, capital-intensive clinical development phase without commercial revenue.
The persistent negative ROIC reflects a business model that is currently consuming capital rather than compounding it. Investors should monitor whether the company can ever achieve a positive return profile, as the current trajectory suggests that every dollar invested is being eroded by high R&D and administrative overhead.
According to recent SEC filings, the company's current ratio has plummeted to 0.15 as of 2024Q4, a dramatic decline from the 19.66 observed in 2024Q2, indicating that the firm lacks the liquid assets necessary to meet its immediate short-term obligations without further dilutive financing.
This rapid deterioration in liquidity suggests that the company is facing an acute funding crisis that threatens its operational continuity. The lack of a buffer between current assets and liabilities implies that the firm is highly vulnerable to even minor disruptions in its cash management or regulatory timelines.
Based on historical data, the company's DPO has fluctuated wildly, reaching as high as 4,549 days in 2023Q1, which suggests that the firm is struggling to manage its supplier relationships and operational payables effectively in the absence of a predictable revenue stream or stable cash flow.
The extreme volatility in payables turnover indicates a lack of operational discipline and potential difficulty in maintaining vendor trust. This inefficiency further complicates the company's ability to manage its limited cash runway, as it appears to be deferring obligations to survive rather than optimizing its working capital cycle.
As noted in market analysis, the use of P/E or EV/EBITDA multiples is fundamentally misapplied to Check-Cap, as these metrics obscure the reality that the company is a pre-revenue clinical-stage entity where valuation should instead be assessed through the lens of cash runway and regulatory milestone probability.
Applying standard valuation multiples to a company with no revenue and negative equity leads to nonsensical results that fail to capture the firm's true risk profile. Investors should instead focus on the probability-weighted net present value of the C-Scan technology and the remaining months of cash available to reach the next regulatory catalyst.
Includes 30+ ratios · 13 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CHEK stock.
Check-Cap Ltd.'s current P/E ratio is -0.4x. This places it at the 50th percentile of its historical range.
Check-Cap Ltd.'s return on equity (ROE) is -226.2%. The historical average is -119.2%.
Based on historical data, Check-Cap Ltd. is trading at a P/E of -0.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.